Document 0517
 DOCN  M9490517
 TI    [Foscarnet for cytomegalovirus retinitis in a patient with acquired
       immunodeficiency syndrome]
 DT    9411
 AU    Nagata Y; Fujino Y; Ono A; Mochizuki M; Mouri H; Oka S; Kimura S;
       Shimada K; Department of Ophthalmology, University of Tokyo School of;
       Medicine, Japan.
 SO    Nippon Ganka Gakkai Zasshi. 1994 Jul;98(7):710-5. Unique Identifier :
       AIDSLINE MED/94346332
 AB    A 41-year-old man with acquired immunodeficiency syndrome (AIDS)
       developed cytomegalovirus (CMV) retinitis. Intravenous administration of
       ganciclovir arrested progression of the retinitis, but it was
       discontinued due to side effects of severe anemia, neutropenia, and
       thrombocytopenia. Reactivation of CMV retinitis occurred two weeks after
       stopping ganciclovir, and then forscarnet was given intravenously. The
       response was prompt with resolution of the retinitis. There was no
       progression of retinitis during the treatment. The patient experienced
       renal dysfunction as a side effect of foscarnet, but it was reversible.
       As with ganciclovir, foscarnet appeared to be an effective drug for CMV
       retinitis associated with AIDS. Both drugs have severe adverse events:
       foscarnet causes renal dysfunction and ganciclovir causes
       myelosuppression, that necessitated discontinuation of the therapy. We
       suggest that alternating ganciclovir and foscarnet administration,
       switching to other treatment on the basis of the clinical response and
       side effects of the drugs, is an efficacious regimen for the treatment
       of CMV retinitis associated with AIDS.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Adult  AIDS-Related
       Opportunistic Infections/*DRUG THERAPY  Case Report  Cytomegalovirus
       Retinitis/COMPLICATIONS/*DRUG THERAPY  English Abstract
       Foscarnet/*THERAPEUTIC USE  Ganciclovir/THERAPEUTIC USE  Human  Male
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).